
|Articles|December 12, 2012
Implant not recommended in UK, but to be launched in European market
The fluocinolone acetonide intravitreal implant (Iluvien, Alimera) has not met the UK’s cost-effectiveness thresholds for treating DME. Alimera has, however, signed an agreement with Quintiles for the implant’s European launch.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
3
Ophthalmic innovation by the decades: The 2010s
4
AAO 2025: Insights on the PULSAR extension study
5